Latest news with #NI51-102
Yahoo
2 days ago
- Business
- Yahoo
Cresco Labs Announces Change of Auditor
CHICAGO, June 12, 2025--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) ("Cresco Labs" or the "Company"), today announced it has changed its auditor from Marcum LLP ("Marcum") to Baker Tilly US, LLP ("Baker Tilly"). Cresco will seek shareholder ratification of Baker Tilly's appointment at the next annual meeting of shareholders. Marcum was terminated as the Company's auditor effective June 9, 2025, and Baker Tilly has been appointed as successor auditor effective June 12, 2025. The change in auditor was recommended and approved by the Company's audit committee and board of directors (the "Board"), respectively. "After an extensive three-month selection process, we are thrilled to appoint Baker Tilly as our independent auditor," said Sharon Schuler, CFO. "With the approval of our Board of Directors, Baker Tilly will begin their engagement with the review of our Q2 2025 financial statements. We are confident in their expertise and look forward to a collaborative partnership as we continue to maintain the highest standards of financial transparency and regulatory compliance." There were no modified opinions in Marcum's audit reports for any financial period during which Marcum was the Company's auditor. There are no "reportable events" (as such term is defined in National Instrument 51-102 Continuous Disclosure Obligations ("NI 51-102")) between the Company and Marcum. In accordance with NI 51-102, the change of auditor notice, together with the required letters from the Marcum and Baker Tilly, have been reviewed and approved, as applicable, by the Board and have been filed on SEDAR+. About Cresco Labs Inc. Cresco Labs' mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production, and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy's, and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development, and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs' journey by visiting or following the Company on Facebook, X or LinkedIn. Forward-Looking Statements This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, "forward-looking statements"). Such forward-looking statements are not representative of historical facts or information or current condition but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as, 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'potential,' or 'continue,' or the negative of those forms or other comparable terms. The Company's forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under "Risk Factors" in the Company's Annual Information Form for the year ended December 31, 2024, filed on SEDAR+ and EDGAR, other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company's forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs' shares, nor as to the Company's financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company's forward-looking statements contained herein, whether as a result of new information, any future event, or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise. View source version on Contacts Media Press@ Investors TJ Cole, Cresco LabsSVP, Corporate Development & Investor Relationsinvestors@ For general Cresco Labs inquiries: 312-929-0993info@ Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Business Wire
2 days ago
- Business
- Business Wire
Cresco Labs Announces Change of Auditor
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (' Cresco Labs ' or the ' Company '), today announced it has changed its auditor from Marcum LLP (' Marcum ') to Baker Tilly US, LLP (' Baker Tilly '). Cresco will seek shareholder ratification of Baker Tilly's appointment at the next annual meeting of shareholders. Marcum was terminated as the Company's auditor effective June 9, 2025, and Baker Tilly has been appointed as successor auditor effective June 12, 2025. The change in auditor was recommended and approved by the Company's audit committee and board of directors (the ' Board '), respectively. 'After an extensive three-month selection process, we are thrilled to appoint Baker Tilly as our independent auditor," said Sharon Schuler, CFO. "With the approval of our Board of Directors, Baker Tilly will begin their engagement with the review of our Q2 2025 financial statements. We are confident in their expertise and look forward to a collaborative partnership as we continue to maintain the highest standards of financial transparency and regulatory compliance." There were no modified opinions in Marcum's audit reports for any financial period during which Marcum was the Company's auditor. There are no "reportable events" (as such term is defined in National Instrument 51-102 Continuous Disclosure Obligations ("NI 51-102")) between the Company and Marcum. In accordance with NI 51-102, the change of auditor notice, together with the required letters from the Marcum and Baker Tilly, have been reviewed and approved, as applicable, by the Board and have been filed on SEDAR+. About Cresco Labs Inc. Cresco Labs' mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production, and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy's, and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development, and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs' journey by visiting or following the Company on Facebook, X or LinkedIn. Forward-Looking Statements This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, 'forward-looking statements'). Such forward-looking statements are not representative of historical facts or information or current condition but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as, 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'potential,' or 'continue,' or the negative of those forms or other comparable terms. The Company's forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under 'Risk Factors' in the Company's Annual Information Form for the year ended December 31, 2024, filed on SEDAR+ and EDGAR, other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company's forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs' shares, nor as to the Company's financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company's forward-looking statements contained herein, whether as a result of new information, any future event, or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.
Yahoo
06-06-2025
- Business
- Yahoo
Aion Therapeutic Announces Change of Auditor
Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that the Company's audit committee and board of directors approved a change in the Company's auditors from DNTW Toronto LLP (the "Former Auditor") to Horizon Assurance LLP (the "Successor Auditor"), effective June 6, 2025. There were no reservations in the Former Auditor's reports for the two most recently completed fiscal years or for any period after the most recently completed period for which an audit report was issued and preceding the date of the Former Auditor's resignation. There are no reportable events, including disagreements, consultations, or unresolved issues as defined in Part 4.11 of National Instrument 51-102 Continuous Disclosure Obligations ("NI 51-102") between the Company and the Former Auditor. The change of auditor notice and associated materials have been filed on the Company's profile on SEDAR+ at About Aion Therapeutic Inc. Aion Therapeutic is a forward-thinking business within the health and wellness sector with a diverse portfolio of intellectual property. With a commitment to innovation and transformative solutions, the Company is poised to drive positive change to redefine the boundaries of health and wellness. Toppen, a wholly-owned subsidiary of Aion Therapeutic, is a US-based innovative health and wellness company dedicated to delivering state-of-the-art water filtration solutions. With a focus on innovation, affordability, and sustainability, Toppen's water filtration solutions are designed to meet the diverse needs of consumers, businesses, and industries around the world as they strive to provide access to clean and safe water. For further information, please contact: Aion Therapeutic SimmondsExecutive Vice Chair & CEO(416) 843-2881 DISCLAIMER & READER ADVISORY This release contains forward-looking information within the meaning of applicable Canadian securities legislation. Expressions such as "anticipates", "expects", "believes", "estimates", "could", "intends", "may", "plans", "predicts", "projects", "will", "would" and other similar expressions, or the negative of these terms, are generally indicative of forward-looking information. Forward looking statements in this press release include statements regarding the completion of the Offering, the timing thereof and the proposed use of proceeds under the Offering. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such forward-looking information. In addition, the forward- looking information contained in this release is based upon what management believes to be reasonable assumptions. Readers are cautioned not to place undue reliance on forward-looking information as it is inherently uncertain, and no assurance can be given that the expectations reflected in such information will prove to be correct. The forward-looking information in this release is made as of the date hereof and, except as required under applicable securities legislation, the Company assumes no obligation to update or revise such information to reflect new events or circumstances. The securities of the Company have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This release is issued for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release. To view the source version of this press release, please visit
Associated Press
29-05-2025
- Business
- Associated Press
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ('Quantum BioPharma'), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the 'Company'), the company behind unbuzzdTM, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, that it has hired leading audit firm MNP LLP ('MNP') effective May 20, 2025, to conduct Public Company Accounting Oversight Board ('PCAOB') audits of the Company's financial statements in preparation for a possible initial public offering ('IPO'). The Company's predecessor auditor, Stern & Lovrics LLP (the 'Predecessor Auditor') resigned effective May 20, 2025, at the Company's request, and the Company's board of directors, upon the audit committee's recommendation, appointed MNP to fill the resulting vacancy until the close of the next annual meeting of the Company's shareholders. MNP, registered with the PCAOB, has the experience and proven track record to deliver audits of the highest standard. Hiring MNP follows the Company's announcement on February 5, 2025, regarding their retention of a New York investment bank to advise on a capital raise and explore an IPO, pending regulatory approval. John Duffy, CEO of Unbuzzd Wellness Inc. stated, 'This engagement of audit firm MNP demonstrates that we adhere to the highest standards in the industry. MNP has worked hard to understand our business and their PCAOB-level audits will prepare Unbuzzd Wellness for a possible IPO.' Mr. Duffy has more than two decades of experience in leadership positions in the beverage industry, including as former VP of Marketing Assets and VP of National Sales at Coca-Cola.' Gerry David, Board Co-Chair and former CEO of Celsius Holdings with their bestselling energy drink Celsius Energy, added, 'Completing our PCAOB audits with MNP represents another important step in ensuring our continued success and strength as we raise capital and consider the possibility of an IPO.' The change of auditor notice required pursuant to National Instrument 51-102 – Continuous Disclosure Obligations ('NI 51-102') and associated material have been filed on SEDAR+ ( under the Company's profile within the prescribed time period. There were no reservations or modified opinions in any auditor's reports nor any reportable events as defined in NI 51-102 in connection with the audits by the Predecessor Auditor of the Company's most recently completed financial year or any subsequent period. Name Change In addition, the Company has changed its name to 'Unbuzzd Wellness Inc.' effective May 23, 2025 (the 'Name Change'). The board of directors of the Company approved the Name Change in accordance with the articles of the Company. The Company's new CUSIP is 90429T100 and its new ISIN is CA90429T1003. Shareholders are not required to exchange existing share certificates for new share certificates bearing the Company's new name. The Name Change does not affect the rights of the Company's shareholders and no further action is required by existing shareholders. About Quantum BioPharma Ltd. Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ('Lucid'), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information on Quantum BioPharma, please visit About Unbuzzd Wellness Inc. The Company, a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class research and development team in pharmacology and medicine, with a commitment to innovation and quality. With a proprietary blend of vitamins, minerals and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly. unbuzzd appeals to a broad audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day. Scientifically-backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration, restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. The full press release of the clinical trial can be found here. unbuzzd ready-to-mix powder sticks are available in 3-pack, 8-pack, and 18-pack formats at and unbuzzd is a registered trademark of the Company. Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE. For more information on Unbuzzd Wellness Inc. please visit Forward-Looking Information Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as 'may', 'should', 'anticipate', 'expect', 'potential', 'believe', 'intend' or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such. Forward-looking information in this press release are based on certain assumptions and expected future events. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at and on the EDGAR section of the United States Securities and Exchange Commission's website a more complete discussion of such risk factors and their potential effects. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those Quantum BioPharma Ltd. Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board Email: [email protected] Telephone: (833) 571-1811 Investor Relations Investor Relations: [email protected] General Inquiries: [email protected]
Associated Press
18-03-2025
- Business
- Associated Press
Gold Mountain Reports its Interim Q4 2025 Financial and Operating Results
VANCOUVER, BC / ACCESS Newswire / March 17, 2025 / Gold Mountain Mining Corp. ('Gold Mountain' or the 'Company') (TSX:GMTN)(OTCQB:GMTNF)(FRA:5XFA) reports its financial and operating results for the three months and twelve months ended January 31, 2025 ('Q4 2025"). The Company's Financial Statements and Management's Discussion and Analysis ('MD&A') are available on the Company's profile on SEDAR+ at and on the Company's website. All amounts are expressed in Canadian dollars ("$") unless otherwise noted. Change of Fiscal Year End The Company announces a change to its fiscal year end from January 31 to March 31. Going forward, the Company's financial reporting periods will align with standard calendar quarters (March, June, September, December). This alignment is expected to enhance financial comparisons and benchmarking with industry peers, as many reporting issuers within the mining sector follow the same reporting cycle. As a result of this change, the Company is releasing its interim financial and operating results for the fourth quarter ended January 31, 2025. The Company will file audited financial statements for the 14-month transitional fiscal period ending March 31, 2025. These filings will be submitted by the end of June 2025, in compliance with National Instrument 51-102 - Continuous Disclosure Obligations ('NI 51-102"). Further details regarding the change in fiscal year end, including the Company's interim reporting procedures, will be available in the Company's Notice of Change of Financial Year- End, prepared in accordance with section 4.8 of NI 51-102, which will be filed on the Company's profile on SEDAR+ at Highlights for the three months ended January 31, 2025 Low production results realized during the reporting period were directly attributable to the planned winter work program, which substantially reduced operations throughout the quarter. As a result, production from the Elk Gold Mine is consistent with the reduced activity level. The combination of lower stripping volumes and the anticipated lower gold production in Q4 2025 resulted in reduced unit costs compared to Q4 2024. Summary of Financial Results For the three months ended January 31, 2025 ('Q4 2025"), the Company recorded a net loss of $1.5 million, compared to a net loss of $2.6 million for the three months ended January 31, 2024 ('Q4 2024"). The reduced loss in Q4 2025 was primarily due to greater metal sales volumes and higher realized gold prices, which resulted in an increase in revenue to $1.2 million, compared to $0.4 million in Q4 2024. Mine operating loss for Q4 2025 was $0.3 million, a significant improvement compared to the mine operating loss of $1.8 million in Q4 2024. The improvement reflects increased production volumes and better cost management during the quarter. Q4 2025 Q4 2024 12MO 2025 12MO 2024 Revenue $ 761,433 $ 424,099 $ 2,349,397 $ 8,576,009 Cost of sales (1,104,793 ) (2,265,257 ) (8,285,105 ) (11,806,694 ) Mine operating loss (343,360 ) (1,841,158 ) (5,935,708 ) (3,230,685 ) Net loss and comprehensive loss (1,457,550 ) (2,626,708 ) (13,212,456 ) (5,922,973 ) Net loss per share - basic and diluted (0.00 ) (0.03 ) (0.02 ) (0.07 ) Adjusted EBITDA1 $ 139,913 $ (2,457,593 ) $ (7,247,798 ) $ (4,836,938 ) Average realized gold price1 ($/oz) $ 2,583 $ 1,263 $ 2,163 $ 2,167 Total Cash Costs1 per ounce sold ($/oz) $ 3,272 $ 6,455 $ 7,189 $ 2,821 Summary of Operational Results Q4 2025 Q4 2024 12MO 2025 12MO 2024 Ore mined (t) 10,055 1,455 31,321 34,017 Waste mined (t) 398,662 199,748 1,296,929 1,623,010 Total mined (t) 408,717 201,203 1,328,250 1,657,027 Ore delivered (t) 8,994 4,187 30,064 33,245 Average ore grade delivered - gold (g/t) 1.23 2.89 1.34 4.26 Strip ratio waste/ore 39.6 137.3 41.4 47.7 Gold ounces sold (oz) 291 327 1,070 3,916 During the three months ended January 31, 2025 ('Q4 2025"), the Company mined a total of 10,055 tonnes of ore and 398,662 tonnes of waste, all sourced from the Siwash North Pit. The average ore grade delivered during the quarter was 1.23 g/t gold, resulting in total gold ounces sold of 291. The strip ratio for the quarter was 39.6. In comparison, during the three months ended January 31, 2024 ('Q4 2024"), the Company mined a total of 1,455 tonnes of ore and 199,748 tonnes of waste from the Siwash North Pit. The average ore grade delivered was 2.89 g/t gold, resulting in total gold ounces sold of 327. The strip ratio in Q4 2024 was significantly higher at 137.3. Corporate Update During the twelve months ended January 31, 2025, the Company incurred a net loss of $13.2 million, reflecting ongoing operational challenges at the Elk Mine. Based on the Elk Mine operations and financial reporting for the twelve months ended January 31, 2025, the Company has commenced an internal review of its National Instrument 43-101 - Standards of Disclosure for Mineral Projects ('NI 43-101") compliant independent Technical Report for the Elk Mine titled 'National Instrument 43-101 Technical Report and Resource Update on the Elk Gold Project, Merritt, British Columbia, Canada' prepared by L. John Peters, Gregory Z. Mosher, and Marinus Andre De Ruijter, P. Eng, each an independent 'Qualified Person' as defined in NI 43-101, with an effective date of December 7, 2021, and a report date of January 21, 2022 (the 'Technical Report'). Accordingly, readers are cautioned to not place undue reliance on the Technical Report or the resource estimate included therein until the Company has completed and reported on its internal review. As part of its internal review, Gold Mountain intends to engage in various activities, including: infill drilling; drilling new holes as quality checks on historical works and findings; re-logging historical drill core; and evaluating existing drill core data. The Company anticipates completing the internal review by July 2025 and will provide an update in due course. Gold Mountain also anticipates receiving the results of exploration drilling which has commenced on the 'Bullion Zone', an area located immediately north of the Siwash Pit. Preliminary observations support additional exploitation and expansion of the existing operational plan for that location. Further, Gold Mountain looks forward to the Elk Mine resuming normal operations following spring melt and the completion of the internal review. About Gold Mountain Gold Mountain is a British Columbia based gold and silver production, exploration and development company focused on the development of the Elk Gold Mine, a producing mine located 57 kilometers from Merritt in South Central British Columbia. Additional information is available at or on the Company's new website at For more information, please contact: Gold Mountain Mining Corp. Email: [email protected] Website: The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release. Forward Looking Statements Forward-looking statements in this news release may include, but are not limited to, statements relating to those in respect of the Company's future financial reporting. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. The forward-looking statements contained in this news release are made as of the date hereof, and except as may be required by applicable securities laws, the Company assumes no obligation or intent to update publicly or revise any forward-looking statements made herein or otherwise, whether as a result of new information, future events or otherwise. 1) The Company has included certain non-IFRS measures in this document, as discussed below. Adjusted earnings before interest, taxes, depreciation and amortization ('EBITDA') is a non-IFRS financial performance measure. For a full definition and reconciliation of this non-IFRS financial performance measure, refer to the Company's MD&A for the three and twelve months ended January 31, 2025, a copy of which is available on the Company's profile at Total Cash Cost per ounce sold is a common financial performance measure in the gold mining industry but has no standard meaning under IFRS. The Company reports total cash costs on a sales basis. For a full definition and reconciliation of this non-IFRS financial performance measure, refer to the Company's MD&A for the three and twelve months ended January 31, 2025, a copy of which is available on the Company's profile at Average realized price per ounce of gold sold is used by management to better understand the price realized in each reporting period for gold sales. This metric is intended to provide additional information only and does not have any standardized definition under IFRS. For a full definition and reconciliation of this non-IFRS financial performance measure, refer to the Company's MD&A for the three and twelve months ended January 31, 2025, a copy of which is available on the Company's profile at
